SARS-CoV Spike Protein-expressing Recombinant Vaccinia Virus Efficiently Induces Neutralizing Antibodies in Rabbits Pre-immunized with Vaccinia Virus

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2006 Oct 3

PMID 17011679

Citations 15

Authors

Masahiro Kitabatake

Shingo Inoue

Fumihiko Yasui

Shoji Yokochi

Masaaki Arai

Kouichi Morita

Hisatoshi Shida

Minoru Kidokoro

Fukashi Murai

Mai Quynh Le

Kyosuke Mizuno

Kouji Matsushima

Michinori Kohara

Affiliations

Soon will be listed here.

Abstract

A vaccine for severe acute respiratory syndrome (SARS) is being intensively pursued against its re-emergence. We generated a SARS coronavirus (SARS-CoV) spike protein-expressing recombinant vaccinia virus (RVV-S) using highly attenuated strain LC16m8. Intradermal administration of RVV-S into rabbits induced neutralizing (NT) antibodies against SARS-CoV 1 week after administration and the NT titer reached 1:1000 after boost immunization with RVV-S. Significantly, NT antibodies against SARS-CoV were induced by administration of RVV-S to rabbits that had been pre-immunized with LC16m8. RVV-S can induce NT antibodies against SARS-CoV despite the presence of NT antibodies against VV. These results suggest that RVV-S may be a powerful SARS vaccine, including in patients previously immunized with the smallpox vaccine.

Citing Articles

Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.

Watanabe S, Yoshikawa T, Kaku Y, Kurosu T, Fukushi S, Sugimoto S PLoS Negl Trop Dis. 2023; 17(12):e0011851.

PMID: 38100536 PMC: 10756534. DOI: 10.1371/journal.pntd.0011851.

B cell receptor repertoire analysis from autopsy samples of COVID-19 patients.

Iwabuchi S, Tsukahara T, Okayama T, Kitabatake M, Motobayashi H, Shichino S Front Immunol. 2023; 14:1034978.

PMID: 36911681 PMC: 9996338. DOI: 10.3389/fimmu.2023.1034978.

An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from....

Ishigaki H, Yasui F, Nakayama M, Endo A, Yamamoto N, Yamaji K Front Microbiol. 2022; 13:967019.

PMID: 36466631 PMC: 9716133. DOI: 10.3389/fmicb.2022.967019.

A replication-competent smallpox vaccine LC16m8Δ-based COVID-19 vaccine.

Sakamoto A, Osawa H, Hashimoto H, Mizuno T, Hasyim A, Abe Y Emerg Microbes Infect. 2022; 11(1):2359-2370.

PMID: 36069348 PMC: 9527789. DOI: 10.1080/22221751.2022.2122580.

Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.

Souza Dos-Santos J, Firmino-Cruz L, da Fonseca-Martins A, Oliveira-Maciel D, Perez G, Roncaglia-Pereira V Front Immunol. 2022; 13:884760.

PMID: 35844561 PMC: 9281395. DOI: 10.3389/fimmu.2022.884760.

References

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S . A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004; 16(10):1423-30. PMC: 7108621. DOI: 10.1093/intimm/dxh143. View

Gallagher T, Buchmeier M . Coronavirus spike proteins in viral entry and pathogenesis. Virology. 2001; 279(2):371-4. PMC: 7133764. DOI: 10.1006/viro.2000.0757. View

Sugimoto M, Yasuda A, Miki K, Morita M, Suzuki K, Uchida N . Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains. Microbiol Immunol. 1985; 29(5):421-8. DOI: 10.1111/j.1348-0421.1985.tb00843.x. View

Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z . Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis. 2004; 190(6):1119-26. PMC: 7199490. DOI: 10.1086/423286. View

Czub M, Weingartl H, Czub S, He R, Cao J . Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005; 23(17-18):2273-9. PMC: 7115540. DOI: 10.1016/j.vaccine.2005.01.033. View

Gao W, Tamin A, Soloff A, DAiuto L, Nwanegbo E, Robbins P . Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003; 362(9399):1895-6. PMC: 7112457. DOI: 10.1016/S0140-6736(03)14962-8. View

Yang Z, Kong W, Huang Y, Roberts A, Murphy B, Subbarao K . A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004; 428(6982):561-4. PMC: 7095382. DOI: 10.1038/nature02463. View

Hammarlund E, Lewis M, Hansen S, Strelow L, Nelson J, Sexton G . Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003; 9(9):1131-7. DOI: 10.1038/nm917. View

10.

Normile D, Enserink M . SARS in China. Tracking the roots of a killer. Science. 2003; 301(5631):297-9. DOI: 10.1126/science.301.5631.297. View

11.

Wang Y, Sin W, Xu G, Yang H, Wong T, Pang X . T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol. 2004; 78(11):5612-8. PMC: 415819. DOI: 10.1128/JVI.78.11.5612-5618.2004. View

12.

Chen Z, Zhang L, Qin C, Ba L, Yi C, Zhang F . Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005; 79(5):2678-88. PMC: 548443. DOI: 10.1128/JVI.79.5.2678-2688.2005. View

13.

Spaan W, Cavanagh D, Horzinek M . Coronaviruses: structure and genome expression. J Gen Virol. 1988; 69 ( Pt 12):2939-52. DOI: 10.1099/0022-1317-69-12-2939. View

14.

Li W, Moore M, Vasilieva N, Sui J, Wong S, Berne M . Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450-4. PMC: 7095016. DOI: 10.1038/nature02145. View

15.

Drosten C, Gunther S, Preiser W, van der Werf S, Brodt H, Becker S . Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1967-76. DOI: 10.1056/NEJMoa030747. View

16.

Buchholz U, Bukreyev A, Yang L, Lamirande E, Murphy B, Subbarao K . Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A. 2004; 101(26):9804-9. PMC: 470755. DOI: 10.1073/pnas.0403492101. View

17.

Jin N, Funahashi S, Shida H . Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression. Arch Virol. 1994; 138(3-4):315-30. DOI: 10.1007/BF01379134. View

18.

Kim T, Lee J, Hung C, Peng S, Roden R, Wang M . Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol. 2004; 78(9):4638-45. PMC: 387705. DOI: 10.1128/jvi.78.9.4638-4645.2004. View

19.

Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K . Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol. 2004; 78(7):3572-7. PMC: 371090. DOI: 10.1128/jvi.78.7.3572-3577.2004. View

20.

Keng C, Zhang A, Shen S, Lip K, Fielding B, Tan T . Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol. 2005; 79(6):3289-96. PMC: 1075733. DOI: 10.1128/JVI.79.6.3289-3296.2005. View